Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H12O6 |
Molecular Weight | 336.295 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(CC2=C(O)C3=CC=CC=C3OC2=O)C(=O)OC4=CC=CC=C14
InChI
InChIKey=DOBMPNYZJYQDGZ-UHFFFAOYSA-N
InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2
Molecular Formula | C19H12O6 |
Molecular Weight | 336.295 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB00266Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728
Sources: https://www.drugbank.ca/drugs/DB00266
Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728
Dicumarol is an coumarin-like compound found in sweet clover. It is used as oral anticoagulant and acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (prothrombin and factors VII, IX, and X). It results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. Dicumarol is also used in biochemical experiments as an inhibitor of reductases.
Originator
Sources: http://www.jbc.org/content/138/1/21.full.pdf
Curator's Comment: Campbell, H.A. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry, 138, 21–33.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1930 Sources: https://www.drugbank.ca/drugs/DB00266 |
2.0 µM [IC50] | ||
Target ID: CHEMBL3623 Sources: https://www.drugbank.ca/drugs/DB00266 |
10.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugbank.ca/drugs/DB00266 |
Preventing | DICUMAROL Approved UseFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis. Launch Date-8.0222401E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
521 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.84 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.03% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 59.8+15.3 years n = 71 Health Status: unhealthy Age Group: 59.8+15.3 years Sex: M+F Population Size: 71 Sources: |
|
2100 mg single, oral Overdose |
unknown n = 1 |
Disc. AE: Distended blood vessels... AEs leading to discontinuation/dose reduction: Distended blood vessels (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Distended blood vessels | 1 patient Disc. AE |
2100 mg single, oral Overdose |
unknown n = 1 |
PubMed
Title | Date | PubMed |
---|---|---|
Unusual gastrointestinal reaction to bishydroxycoumarin(Dicumarol). | 1968 Jul |
|
Urinary tract complications of anticoagulation therapy; "pseudotumour" of the kidney. | 1968 Mar |
|
Intraocular hemorrhage and blindness associated with systemic anticoagulation. | 1972 Jun 5 |
|
Activation and deactivation of quinones catalyzed by DT-diaphorase. Evidence for bioreductive activation of diaziquone (AZQ) in human tumor cells and detoxification of benzene metabolites in bone marrow stroma. | 1990 |
|
[Fatal cerebral hemorrhage caused by overdose of dicumarol, report of a case]. | 1992 Feb |
|
Reduction of chromium(VI) to chromium(V) by rat liver cytosolic and microsomal fractions: is DT-diaphorase involved? | 1992 Jul |
|
Aspirin-like drugs can protect human T lymphocytes against benzoquinone cytotoxicity: evidence for a NAD(P)H:quinone reductase-dependent mechanism. | 1995 |
|
Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations. | 1995 Apr |
|
Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. | 1996 May 10 |
|
Roles of DT diaphorase in the genotoxicity of nitroaromatic compounds in human and fish cell lines. | 1997 Oct 10 |
|
The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells. | 1997 Oct 15 |
|
Fulminant hepatic failure associated with dicoumarol therapy. | 1998 Feb |
|
Chromium (VI)-induced cytotoxicity to osteoblast-derived cells. | 1999 Dec |
|
Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. | 2001 Apr |
|
Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol. | 2001 Jun 1 |
|
P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. | 2003 Dec 9 |
|
Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol. | 2003 Mar 15 |
|
Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. | 2003 Sep 1 |
|
Geomorphological evolution and environmental reclamation of Fusaro Lagoon (Campania Province, southern Italy). | 2004 Apr |
|
Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. | 2004 Jul 1 |
|
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. | 2004 May 1 |
|
Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. | 2005 Apr 1 |
|
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. | 2005 Feb |
|
Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression. | 2006 Aug 1 |
|
Molecular cloning of a novel type of rat cytoplasmic 17beta-hydroxysteroid dehydrogenase distinct from the type 5 isozyme. | 2006 Jun |
|
[Proteus penneri]. | 2006 Oct |
|
Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target. | 2007 Dec |
|
Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells. | 2007 Nov 1 |
|
The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells. | 2009 Jul 15 |
|
Low levels of the air pollutant 1-nitropyrene induce DNA damage, increased levels of reactive oxygen species and endoplasmic reticulum stress in human endothelial cells. | 2009 Jul 28 |
|
Cost-effective interrogation of single nucleotide polymorphisms using the mismatch amplification mutation assay and capillary electrophoresis. | 2010 Dec |
|
Finding new enzymes from bacterial physiology: a successful approach illustrated by the detection of novel oxidases in Marinomonas mediterranea. | 2010 Mar 5 |
|
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. | 2010 Oct 6 |
|
Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. | 2011 Aug |
|
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists. | 2011 Oct 27 |
|
NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with 20S proteasome for binding with C/EBPα leading to its stabilization and protection against radiation-induced myeloproliferative disease. | 2012 Dec 7 |
|
Stress-induced NQO1 controls stability of C/EBPα against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer. | 2012 Oct 4 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2113031
Dicoumarol inhibits rat liver microsomal vitamin K epoxide reductase with IC50=2 uM and cytosolic DT-diaphorase with IC50=0.05 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:06:24 UTC 2023
by
admin
on
Fri Dec 15 15:06:24 UTC 2023
|
Record UNII |
7QID3E7BG7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C45597
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
||
|
WHO-VATC |
QB01AA01
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
||
|
WHO-ATC |
B01AA01
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07101MIG
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
DB00266
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
17860
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
3223
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
DICOUMAROL
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
4513
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
DICUMAROL
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | Description: A white or creamy white, crystalline powder; odour, characteristic, faint.Solubility: Practically insoluble in water, ethanol (~750 g/l) TS and ether R.Category: Anticoagulant.Storage: Dicoumarol should be kept in a well-closed container, protected from light.Definition: Dicoumarol contains not less than 98.5% and not more than 101.0% of C19H12O6, calculated with reference to the dried substance. | ||
|
7QID3E7BG7
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
D001728
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
221570
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
54676038
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
100000082921
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
6808
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
dicoumarol
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
2897
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
200-632-9
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
1598
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1466
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
41834
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
C310
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
66-76-2
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
867
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | |||
|
m4370
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID8021729
Created by
admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |